Study Assuages Fears of Pancreatic Cancer Risk With GLP-1 Receptor Agonists
Several years after initiating treatment, GLP-1 receptor agonist users didn’t have a pancreatic cancer safety signal, a historical cohort study reported. Compared with basal insulin users, those on a GLP-1 receptor agonist didn’t have a significantly different risk for developing pancreatic cancer in the 5 to 7 years that followed (HR 0.50, 95% CI 0.15-1.71), […]
Can a GLP-1 Agonist Improve Parkinson’s Symptoms?
An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with placebo, a phase II trial showed. Neither 2.5 mg or 5.0 mg of weekly NLY01 injections showed any difference from placebo in the sum of Movement […]
Low-Dose Semaglutide Can Ease Insulin Need in Early T1D, Small Series Shows
When used very early on in type 1 diabetes, a GLP-1 receptor agonist may help reduce the need for insulin, a small case series suggested. Ten adults with a new type 1 diabetes diagnosis initially received a 0.125-mg dose of weekly semaglutide (Ozempic), which was adjusted up to a maximum of 0.5 mg per week […]
Novel Triple Agonist Nabs Biggest Weight Loss Yet in Obesity Trial
SAN DIEGO — An investigational triple-hormone receptor agonist yielded major weight loss in people with obesity, a phase II trial showed. By 24 weeks, patients on any of the four doses of once-weekly injectable retatrutide lost a significantly greater amount of weight than those on placebo — achieving the trial’s primary endpoint — reported Ania […]
Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial
SAN DIEGO — Orforglipron, an investigational nonpeptide GLP-1 receptor agonist, helped people with obesity lose a significant amount of weight in a phase II trial. Tested at four once-daily doses — 12, 24, 36, or 45 mg — patients on orforglipron lost between 8.6% to 12.6% of body weight compared with a 2% change seen […]
Buprenorphine for Chronic Pain, Not Full Agonist Opioids, New VA Guidance Says
Buprenorphine, rather than a full agonist opioid, should be used for patients taking daily opioids for chronic pain, given its lower risk for overdose or misuse, new guidelines from the Department of Veterans Affairs (VA) and Department of Defense (DoD) recommended. But “the guideline development group does not recommend use of opioid analgesics in the […]
Oral Drug Shows Benefit for Notalgia Paresthetica in Mid-Stage Trial
A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to “modestly” greater improvements in itchiness over placebo, but was associated with adverse events, a randomized phase II trial showed. At 8 weeks, improvements in average itchiness was significantly greater with oral difelikefalin (Korsuva) versus placebo on the Worst Itch Numeric Rating Scale […]
‘Modest’ Erectile Dysfunction Benefit With GLP-1 Agonist
GLP-1 receptor agonist treatment in men with type 2 diabetes may thwart some new cases of erectile dysfunction, an exploratory analysis of a randomized trial suggested. The findings, from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial, showed that slightly fewer men developed erectile dysfunction while on long-term treatment with once-weekly […]